Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05013632

COVID-19 International Drug Pregnancy Registry

Sponsor: Pregistry

View on ClinicalTrials.gov

Summary

The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.

Official title: COVID-19 International Drug Pregnancy Registry (COVID-PR)

Key Details

Gender

FEMALE

Age Range

18 Years - 50 Years

Study Type

OBSERVATIONAL

Enrollment

2000

Start Date

2021-12-01

Completion Date

2027-09-30

Last Updated

2025-09-26

Healthy Volunteers

No

Conditions

Interventions

DRUG

Antiviral Agents

Antiviral medications indicated for the treatment of mild to severe COVID-19

DRUG

Monoclonal antibody

Monoclonal antibodies indicated for the treatment of mild to severe COVID-19

Locations (1)

Pregistry

Los Angeles, California, United States